A retrospective cohort study analyzed 29,922 patients with T2D and obesity-related HFpEF on SGLT2 inhibitors, comparing 7,044 patients who received additional GLP-1 RA therapy (including semaglutide) with 7,044 on SGLT2 inhibitors alone over 12 months [30]. Here, SLC5A2 is linked to type 2 diabetes mellitus.